Le Lézard
Classified in: Health
Subject: EGV

The European Society of Endocrinology Meets With European Parliament Members to Discuss Limiting the Socioeconomic Impact of Osteoporosis in Europe


MILAN, October 18, 2018 /PRNewswire/ --

In Brussels, the European Society of Endocrinology has met 10 European Parliament members and proposed a shared agenda to limit the socioeconomic impact of Osteoporosis in Europe.

Tackling hypovitaminosis D, early diagnosis of vertebral fractures, access and adherence to therapies are the key points to work on.

     (Logo: https://mma.prnewswire.com/media/770911/The_European_Society_of_Endocrinology_Logo.jpg )

Affecting more than half of population aged over 80, osteoporosis represents an emergency in terms of social relevance and economic - healthcare costs.  The European Society of Endocrinology seizes the opportunity of the World Osteoporosis Day to meet European Authorities and set forth a proposal of shared healthcare policies that may produce large-scale benefits and improve people's health and State budgets.

 

"Fragility fractures have an important economic impact.  The direct costs (hospitalizations) only in Italy account for around 9 billion euros. 1 more billion of indirect costs, such as rehabilitation costs and losses due to absence from work, has to be added. We find the same situation in the rest of EU States as well - says Prof. Andrea Giustina, Professor of Endocrinology at San Raffaele Hospital in Milan and President-Elect of the European Society of Endocrinology - The three-point document we will set forth to the EP members proposes some cost-effective measures of clinical practice aimed at limiting costs and drastically reducing the incidence of this disease."

The document prepared by the ESE is set out in 3 points:


"European endocrinologists wish that this agenda of intervention might gain the widest consent among Institutions and are ready to help in order to find in practice the most effective instruments to implement intervention on the mentioned criticalities. They also commit themselves to verify the execution and effectiveness of said instruments 12 months hence," concludes Giustina.


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: